New treatment approaches
There is a subset of asthmatic patients who, despite treatment with optimal doses of asthma medications, have uncontrolled asthma and are at risk for severe asthma exacerbations. These are considered severe refractory asthmatics, and constitute from 5% to 10% of the asthma population.
7 This is the group of patients where phenotyping (determining patient characteristics), with relation to their atopic status and the type of airway inflammation present, may provide additional useful information with regards to treatment options. Indeed, a number of new treatment approaches have been identified for patients with severe refractory asthma, which have targeted therapy against specific inflammatory cell types thought to be important in the persistence of asthma, or in severe asthma exacerbations.
Targeting airway eosinophilia One of these new approaches was developed as a result of the identification of patients with severe refractory asthma, who have persistent airway eosinophilia.
8 Studies have demonstrated that inhibition of airway eosinophilia with a humanized monoclonal antibody against interleukin (IL)-5 (mepolizumab) reduces the risk of severe asthma exacerbations 9, 10 and can improve lung function and asthma control.
11 A subsequent larger double-blind, placebo-controlled trial was reported of the effects of treatment with mepolizumab in a population of patients with a history of recurrent severe asthma exacerbations, and evidence of eosinophilic inflammation (FIGURE 2).
12 Patients were treated with 1 of 3 doses of intravenous mepolizumab or placebo over 1 year. The rate of severe asthma exacerbations was significantly reduced by 50% with mepolizumab treatment, with no evidence of increasing benefit with increasing doses of treatment. Taken together, these studies indicate study has evaluated the potential benefit of a selective CRTh2 antagonist in asthma.
16 In contrast to the above studies, patients enrolled into this trial were not using regular ICS to manage their asthma. Treatment with the antagonist significantly improved the forced expiratory volume in 1 second (FEV 1 ) -by 9.2% compared with 1.8% with placebo (but only in the per-protocol population). There were also significant improvements in the quality of life scores and night-time symptoms. The magnitude of clinical benefit is, however, less than the one that would be observed with low doses of ICS in this patient population. Another recently published short-term study of 12 weeks evaluated the benefit of a CRTh2 antagonist in asthmatic patients not controlled while on ICS treatment, and described no benefit on asthma control.
17 It appears unlikely that this treatment approach will benefit patients with severe refractory asthma.
Antimuscarinics Another new treatment approach for patients uncontrolled while on treatment with the combination of ICS/LABA has been the evaluation of inhaled long-acting muscarinic antagonists (LAMAs), which are the mainstay of treatment for chronic obstructive pulmonary disease, but have not yet been demonstrated useful in asthma. Two replicate, randomized, placebo--controlled trials evaluated the benefit of the LAMA tiotropium or placebo for 48 weeks, when added to treatment, on lung function and asthma exacerbations.
18,19 Treatment with tiotropium significantly improved the trough (pre-dose) FEV 1 from baseline in both studies, when compared that targeting IL-5 will provide substantial clinical benefit in patients with severe refractory asthma and persistent airway eosinophilia.
Targeting airway neutrophilia About half of the patients with asthma have a noneosinophilic airway inflammation, which is often neutrophilic.
13 It is unclear, however, whether neutrophils contribute to the lack of asthma control or to exacerbations. Neutrophil migration is, in part, mediated by activation of a chemokine receptor CXCR2, which is a G-protein-coupled receptor, amenable to antagonism by small-molecular-weight antagonists and with a number of agonists, including IL-8 and growth-regulated oncogene α and β. One such antagonist (SCH527123) was studied in a small randomized, 4-week, double-blind study in 32 patients with severe refractory asthma and airway neutrophilia.
14 Treatment with SCH527123 caused a significant reduction in both blood and sputum neutrophils, with significantly fewer mild exacerbations and a trend towards improvement in the asthma control questionnaire score. This study suggests that airway neutrophils may play a role in the persistence of severe refractory asthma in some patients, but larger studies of longer duration are needed to evaluate the effect on other outcomes of asthma, including severe exacerbations.
Targeting T-helper type 2 cells CRTH2 is another G-protein-coupled receptor that has been implicated in asthma, via the activation of T-helper 2 lymphocytes, eosinophils, and basophils by prostaglandin D 2 . 15 A double-blind, placebo-controlled begin treatment with these compounds. Antagonists of CRTh2 are unlikely to be of great benefit in the management of severe refractory asthma. Tiotropium will likely be used as an add-on to ICS/LABA, as most patients with severe refractory asthma have airflow obstruction. Bronchial thermoplasty will provide benefit in a subgroup of patients who remain symptomatic despite the absence of ongoing airway inflammation.
